VIRACTA THERAPEUTICS

Viracta Therapeutics to Host R&D Day on October 4, 2023

05 9 2023 09:00:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Announces New Employment Inducement Grant

18 8 2023 16:05:03 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

14 8 2023 08:00:01 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

08 8 2023 08:30:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

07 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)

28 6 2023 08:00:01 提供 Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

31 5 2023 16:15:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

11 5 2023 16:05:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

08 5 2023 16:05:01 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Announces Departure of Chief Medical Officer

02 5 2023 16:05:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

19 4 2023 16:30:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

13 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

08 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

07 2 2023 16:05:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma

19 1 2023 08:30:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

08 1 2023 13:00:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress

30 11 2022 18:10:00 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Announces New Employment Inducement Grant

21 11 2022 17:08:25 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Announces New Employment Inducement Grant

14 11 2022 16:42:22 提供 Nasdaq GlobeNewswire

Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs

10 11 2022 16:05:03 提供 Nasdaq GlobeNewswire